98%
921
2 minutes
20
Gold electrodes (GE) were modified by the deposition of copper nanoparticles (CuNPs) and cobalt nanoparticles (CoNPs), followed by drop-casting of the ferrocene derivative FcCO-Glu-Cys-Gly-OH (Fc-ECG), resulting in two enzyme-free electrochemical sensors Fc-ECG/CuNPs/GE and Fc-ECG/CuNPs/GE. The ferrocene-peptide conjugate acts as an effective redox mediator for glucose oxidation, while metal nanoparticles acted as non-biological sites for glucose oxidation. Field emission scanning electron microscopy (FESEM), cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) were carried out for characterization, while differential pulse voltammetry (DPV) was used for glucose quantification. Under optimized conditions, DPV shows a linear relationship between glucose concentration and the peak current. Both sensors showed a surprisingly high sensitivity of 217.27 and 378.70 μA mM cm, respectively. A comparison to other glucose sensors shows a sensitivity that is 25 times higher. The sensors exhibit good reproducibility, stability, and repeatability. In injection experiments, recovery rates were 87.39-107.65% and 100.00-106.88%, respectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981370 | PMC |
http://dx.doi.org/10.1039/d1ra09213h | DOI Listing |
NMR Biomed
October 2025
High-Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
The human kidneys play a pivotal role in regulating blood pressure, water, and salt homeostasis, but assessment of renal function typically requires invasive methods. Deuterium metabolic imaging (DMI) is a novel, noninvasive technique for mapping tissue-specific uptake and metabolism of deuterium-labeled tracers. This study evaluates the feasibility of renal DMI at 7-Tesla (7T) to track deuterium-labeled tracers with high spatial and temporal resolution, aiming to establish a foundation for potential clinical applications in the noninvasive investigation of renal physiology and pathophysiology.
View Article and Find Full Text PDFG Ital Nefrol
August 2025
UO Nefrologia e Dialisi, Ospedale di Cassino, Italia.
SGLT-2 inhibitors are a relatively new class of antidiabetic drugs. They activate a transcriptional response similar to calorie restriction characterized by the up-regulation of sensors involved in nutrient deprivation, such as SIRT1 and AMPK, and the down-regulation of mTOR, a molecule involved in nutritional excess signaling. The purpose of this review is to illustrate the main pathways of nutrient deprivation: a complex mechanistic framework partly responsible for the cardio-renal benefits that makes these drugs unique.
View Article and Find Full Text PDFNat Rev Endocrinol
September 2025
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital (USZ) and University of Zurich (UZH), Zurich, Switzerland.
Wearable technologies that analyse non-conventional biological matrices, such as interstitial fluid, sweat, tears or breath, have the potential to provide longitudinal biomarker data with minimal invasiveness. These data could provide insights into physiological and behavioural patterns, in particular outside medical care facilities. Despite the success of continuous glucose monitoring, the adoption of wearable sensors for managing endocrine and metabolic diseases remains limited.
View Article and Find Full Text PDFProg Mol Biol Transl Sci
September 2025
School of Forensic Science, National Forensic Sciences University, Gandhinagar, Gujarat, India.
Ingestible biosensors are a mix of advanced biomedical engineering, digital health and precision pharmacotherapy. These miniaturised electronic devices are encapsulated in biocompatible materials, which operate within gastrointestinal (GI) tract. This enables real-time monitoring of pharmacological and physiological parameters.
View Article and Find Full Text PDFProg Mol Biol Transl Sci
September 2025
Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada. Electronic address:
This chapter, "Implantable Biosensors: Advancements and Applications," provides a succinct overview of the state-of-the-art in implantable biosensor technology, highlighting both established clinical uses and promising areas of ongoing research. It begins by outlining the fundamental principles and advantages of these sensors, such as their precision in physiological monitoring and capability for real-time therapeutic interventions. A variety of implantable sensors are categorized, including biophysical and biochemical types, each designed for specific medical applications.
View Article and Find Full Text PDF